Phibro Animal Health Corporation (PAHC) Cash Flow Statement

The dramatic compression in the OCF/NI ratio during early 2026 indicates that reported earnings are not translating into immediate cash generation, likely due to the integration of acquired inventory and receivables. This volatility warrants close monitoring, as the quality of earnings appears temporarily impaired by the large-scale transaction.

The persistent negative working capital changes since the acquisition suggest the company is funding the build-up of inventory and receivables for the newly acquired product lines. This is a typical post-acquisition phase, but the magnitude indicates a significant cash investment is required to operationalize the deal, temporarily masking underlying cash generation.

The FCF trajectory shows a company in transition. While the recent improvement is positive, the current margin is insufficient to rapidly deleverage the balance sheet. The prior peak in Q3 2025 appears to be an outlier driven by favorable working capital timing, not a sustainable run-rate.

The rising capital intensity is a critical metric to watch. It implies that the acquisition has not yet delivered significant capital expenditure synergies and may have increased the company's maintenance capex requirements. This higher reinvestment rate will further pressure free cash flow until operational efficiencies are realized.

Maintaining the dividend during a period of acquisition-driven cash strain signals management's confidence in long-term cash flows, but it also reduces financial flexibility. With leverage elevated, investors should assess whether this capital could be better deployed toward debt reduction or integration needs.